Published in Clin Ther on February 01, 1999
Pharmacogenomics: the promise of personalized medicine. AAPS PharmSci (2000) 2.63
Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. J Natl Cancer Inst (2012) 2.47
Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med (2013) 2.20
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer (2009) 1.43
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol (2008) 1.35
Phage display in molecular imaging and diagnosis of cancer. Chem Rev (2010) 1.34
Mass spectrometric determination of disulfide linkages in recombinant therapeutic proteins using online LC-MS with electron-transfer dissociation. Anal Chem (2009) 1.24
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine (2012) 1.24
Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol (2010) 1.23
EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. Br J Cancer (2007) 1.21
Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des Devel Ther (2009) 1.17
67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. J Clin Invest (2013) 1.14
Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer (2009) 1.04
Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models. BMC Med (2012) 1.03
Anticancer drug targets: growth factors and growth factor signaling. J Clin Invest (2000) 1.02
HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol (2011) 1.01
IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma. J Clin Pathol (2005) 0.99
Removing T-cell epitopes with computational protein design. Proc Natl Acad Sci U S A (2014) 0.99
Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer (2013) 0.98
Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. Sci Rep (2016) 0.97
Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with (89)Zr(4+): comparison with desferrioxamine-B. Dalton Trans (2015) 0.97
α-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration. Cancer Res (2014) 0.96
Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur J Immunol (2008) 0.93
Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies. Cytotechnology (2007) 0.93
Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer (2001) 0.93
Pharmacogenomics. Interview by Clare Thompson. BMJ (1999) 0.93
ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation. J Cell Biochem (2014) 0.92
Functional human antibody CDR fusions as long-acting therapeutic endocrine agonists. Proc Natl Acad Sci U S A (2015) 0.91
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). Oncoimmunology (2012) 0.91
Construction, MD simulation, and hydrodynamic validation of an all-atom model of a monoclonal IgG antibody. Biophys J (2010) 0.88
Near-infrared quantum dots for HER2 localization and imaging of cancer cells. Int J Nanomedicine (2014) 0.87
Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients. Curr Oncol (2013) 0.86
Formylbenzene diazonium hexafluorophosphate reagent for tyrosine-selective modification of proteins and the introduction of a bioorthogonal aldehyde. Bioconjug Chem (2012) 0.86
Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer. MAbs (2014) 0.85
T cell coinhibition and immunotherapy in human breast cancer. Discov Med (2012) 0.85
Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling. Breast Cancer Res (2014) 0.85
Determination of primary structure and microheterogeneity of a beta-amyloid plaque-specific antibody using high-performance LC-tandem mass spectrometry. Anal Bioanal Chem (2008) 0.85
Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation. Cancer Biother Radiopharm (2013) 0.84
Drug therapy of cancer. Eur J Clin Pharmacol (2011) 0.83
Personalized medicine: a patient-centered paradigm. J Transl Med (2011) 0.83
Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett (2011) 0.83
Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes. Mol Cancer Ther (2014) 0.81
Modulation of P-gp expression by lapatinib. Invest New Drugs (2010) 0.81
A two-step toward personalized therapies for prostate cancer. Sci Transl Med (2011) 0.81
Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma. J Clin Pathol (2005) 0.80
Down-regulation of PAR1 activity with a pHLIP-based allosteric antagonist induces cancer cell death. Biochem J (2015) 0.80
Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer. Oncogene (2016) 0.79
Triplex-forming oligonucleotides targeting c-MYC potentiate the anti-tumor activity of gemcitabine in a mouse model of human cancer. Mol Carcinog (2013) 0.79
Defining the sister rat mammary tumor cell lines HH-16 cl.2/1 and HH-16.cl.4 as an in vitro cell model for Erbb2. PLoS One (2012) 0.79
Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs (2012) 0.78
Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. Circ Heart Fail (2016) 0.78
Pharmacogenomics. West J Med (1999) 0.77
C14orf166 overexpression correlates with tumor progression and poor prognosis of breast cancer. J Transl Med (2016) 0.76
Targeting lymphatic vessel functions through tyrosine kinases. J Angiogenes Res (2010) 0.76
Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer. Int J Clin Exp Pathol (2014) 0.76
Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study. Oncotarget (2016) 0.75
Oxidative Stress Mediates the Antiproliferative Effects of Nelfinavir in Breast Cancer Cells. PLoS One (2016) 0.75
Generation of high-affinity fully human anti-interleukin-8 antibodies from its cDNA by two-hybrid screening and affinity maturation in yeast. Protein Sci (2010) 0.75
Identification of anti-CD98 antibody mimotopes for inducing antibodies with antitumor activity by mimotope immunization. Cancer Sci (2014) 0.75
Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2. Cancer Gene Ther (2016) 0.75
p185, an immunodominant epitope, is an autoantigen mimotope. J Biol Chem (2011) 0.75
The "π-Clamp" Offers a New Strategy for Site-Selective Protein Modification. Chembiochem (2016) 0.75
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. Invest New Drugs (2015) 0.75
HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosis. Int J Clin Exp Pathol (2014) 0.75
Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors. Mol Ther Oncolytics (2016) 0.75
Rational Design of Dual Agonist-Antibody Fusions as Long-acting Therapeutic Hormones. ACS Chem Biol (2016) 0.75
Development of novel drug delivery systems using phage display technology for clinical application of protein drugs. Proc Jpn Acad Ser B Phys Biol Sci (2016) 0.75
HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression. Springerplus (2013) 0.75
Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine. Biomedicines (2016) 0.75